SynBiotic SE (FRA:SBX)
2.505
+0.060 (2.45%)
Jan 23, 2026, 4:00 PM EST
SynBiotic SE Revenue
In the year 2023, SynBiotic SE had annual revenue of 3.86M EUR, down -52.71%. SynBiotic SE had revenue of 3.55M in the quarter ending June 30, 2024.
Revenue
3.86M
Revenue Growth
-52.71%
P/S Ratio
4.41
Revenue / Employee
70.21K
Employees
55
Market Cap
17.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.86M | -4.30M | -52.71% |
| Dec 31, 2022 | 8.17M | -898.09K | -9.91% |
| Dec 31, 2021 | 9.06M | 3.59M | 65.63% |
| Dec 31, 2020 | 5.47M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdCapital AG | 157.83M |
| ACCENTRO Real Estate AG | 77.32M |
| 123fahrschule SE | 25.05M |
| Regenbogen AG | 21.90M |
| tick Trading Software AG | 9.08M |
| Consensus Asset Management AB | 5.69M |
| Your Family Entertainment AG | 2.62M |
| Petro Matad | 1.73M |
SynBiotic SE News
- 11 days ago - EQS-News: Global momentum in the cannabis market: New signals from the U.S. strengthen long-term prospects for Europe and SYNBIOTIC - Wallstreet:Online
- 6 weeks ago - Additional capital to support strategic realignment; chg. PT - Wallstreet:Online
- 6 weeks ago - CANSOUL Invests Strategically in SynBiotic: Stake Acquisition - Wallstreet:Online
- 6 weeks ago - EQS-News: Strategic Investment: CANSOUL acquires stake in SYNBIOTIC - Wallstreet:Online
- 2 months ago - EQS-News: SYNBIOTIC strengthens its presence at international events and monitors advances in cannabis research - Wallstreet:Online
- 3 months ago - EQS-News: SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate - Wallstreet:Online
- 3 months ago - Temporary headwinds from regulatory uncertainty; chg. est. - Wallstreet:Online
- 4 months ago - EQS-News: Positive Outlook: Cannabis Legalization Review and Trump’s Endorsement Send Encouraging Signals - Wallstreet:Online